Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Witt, Russell G., Erstad, Derek J., Wargo, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894940/
https://www.ncbi.nlm.nih.gov/pubmed/35251322
http://dx.doi.org/10.1177/17588359221083052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894940/
https://www.ncbi.nlm.nih.gov/pubmed/35251322
http://dx.doi.org/10.1177/17588359221083052

Ejemplares similares